Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) have earned an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $6.8571.
PYXS has been the topic of a number of research reports. Weiss Ratings cut Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. Leerink Partners reduced their price objective on Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating for the company in a research report on Thursday, July 2nd. Wall Street Zen downgraded Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Wedbush began coverage on Pyxis Oncology in a research report on Tuesday, May 5th. They issued an “outperform” rating and a $6.00 target price on the stock.
View Our Latest Stock Analysis on Pyxis Oncology
Pyxis Oncology Stock Up 5.9%
Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last issued its earnings results on Thursday, May 14th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). Research analysts anticipate that Pyxis Oncology will post -1.19 earnings per share for the current year.
Hedge Funds Weigh In On Pyxis Oncology
Institutional investors have recently modified their holdings of the company. Maia Wealth LLC bought a new stake in Pyxis Oncology in the 4th quarter valued at about $25,000. Engineers Gate Manager LP bought a new position in Pyxis Oncology in the 4th quarter worth about $26,000. Fox Run Management L.L.C. bought a new position in Pyxis Oncology in the 4th quarter worth about $26,000. Avanza Fonder AB acquired a new stake in shares of Pyxis Oncology in the fourth quarter valued at approximately $31,000. Finally, XTX Topco Ltd acquired a new stake in shares of Pyxis Oncology in the second quarter valued at approximately $40,000. Institutional investors own 39.07% of the company’s stock.
Pyxis Oncology Company Profile
Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.
Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.
Featured Stories
- Five stocks we like better than Pyxis Oncology
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
